https://www.selleckchem.com/pr....oducts/defactinib.ht
These results have accordingly led to a downgrade in the current recommendations on the use of ASA for primary prevention. This article provides an overview on the current evidence on the use of aspirin for primary prevention of cardiovascular disease.Aspirin (ASA) is the original antiplatelet agent. Its routine use, long unquestioned for both primary and secondary prevention in cardiovascular disease, is under increasing scrutiny as the riskbenefit balance for ASA becomes less clear and other disease- and risk-modifying approaches a
Like
Comment
Share
